Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy,
with about 100 000 people developing the disorder every year worldwide. Under the …

Background Guillain‐Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral
nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune …

Background Despite the introduction of plasmapheresis and immunoglobulin therapy, many
patients with Guillain-Barré syndrome still have an incomplete recovery. Evidence from …

We report a case of bifacial weakness with paresthesia, a recognized Guillain-Barré
syndrome subtype characterized by rapidly progressive facial weakness and paresthesia …

The epidemiology, clinical characteristics, management and outcome of Guillain–Barré
syndrome (GBS) differ between low-income and middle-income countries (LMIC) and high …

Background The possible risk of Guillain-Barré syndrome from influenza vaccines remains a
potential obstacle to achieving high vaccination coverage. However, influenza infection …

Abstract Background Guillain-Barre syndrome (GBS) is characterized by acute onset and
progressive course, and is usually associated with a good prognosis. However, there are …

Abstract Background/Objective Prognostication is a routine part of the delivery of
neurocritical care for most patients with acute neurocritical illnesses. Numerous prognostic …

Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy affecting 1–
2 subjects per 100,000 every year worldwide. It causes, in its classic form, symmetric …

This study compared the clinical outcomes of the two main neurophysiological types of
Guillain-Barré Syndrome (GBS). Sixty-two GBS patients were examined clinically at onset …